- AU$55.38bn
- AU$72.46bn
- $15.56bn
Australia stocks lose $93 bln in a week as Mideast war weighs after wild earnings season
Australia's CSL to supply vaccines to Canada in case of flu pandemic; shares jump
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Australian shares climb as NAB sets peak, BlueScope jumps on improved bid
CSL signs licensing deal with Eli Lilly for clazakizumab to explore other potential treatments (updated)
Australian shares climb as NAB sets peak, BlueScope jumps on improved bid
Australia's CSL recovers after signing licensing deal with Eli Lilly
CSL licenses Eli Lilly's clazakizumab to cut cardiac risk in end-stage kidney disease (updated)
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Brief: CSL And Lilly Enter Licensing Agreement For Clazakizumab
Brief: CSL Says Neffy, Adrenaline Nasal Spray, Approved To Treat Anaphylaxis In Australia
CSL rout extends into sixth session after CEO departure, weak earnings
Global Markets: Dollar, yields gain, US stocks little changed after US jobs data beat
Global Markets: Stocks, dollar jump after US jobs data beat; AI worries simmer below the surface
Global Markets: Stocks pause for breath as AI worries simmer; yen gallops higher
Global Markets: Stocks pause for breath as AI worries simmer; yen gallops higher
Global Markets: Buoyant stocks pause for breath; yen gallops higher
Biotech CSL fails at administering own medicine
CSL's slump drags Australian healthcare stocks to near 7-year low